Research Summary

Dr. Mary Feng specialized in treatment of gastrointestinal and hepatobiliary cancers. Her research focuses on technical and biological methods to individualize and adapt radiotherapy for each patient with pancreas and liver cancer to maximize the effectiveness of treatment. Her primary goals are 1) Improving outcomes for patients with pancreas and liver cancer through novel combination treatments; 2) Adapting radiotherapy based on early blood and imaging biomarkers of tumor response and treatment effects on nearby organs; and 3) Evaluating the use of advanced technologies in radiotherapy.

Dr. Feng is Vice-Chair for Clinical Research, Clinical site director for the Mission Bay Clinic, and Director of Quality Assurance and Safety for the Department of Radiation Oncology at UCSF. She also serves on numerous national and international cancer organization panels and groups, including the National Comprehensive Cancer Network Pancreatic Adenocarcinoma Panel, the American Society of Clinical Oncology Gastrointestinal Cancer Guideline Advisory Group, and the American Society for Radiation Oncology IHE-RO Clinical Advisory Subcommittee as co-chair.

Education

Stanford University, Stanford, CA, BS with Honors, 06/1997, Biological Sciences

Washington University School of Medicine, MD, 05/2002

University of Michigan Medical Center, Intern, 06/2003, Preliminary Medical

University of Michigan Medical Center, Resident, 06/2006, Radiation Oncology

University of Michigan Medical Center, Chief Resident, 06/2007, Radiation Oncology

Honors & Awards

  • 1996
    Howard Hughes Medical Institute Summer Research Fellowship, Stanford University
  • 1998
    American Red Cross Volunteer of the Year, Palo Alto, CA chapter
  • 1998
    Philpott Scholarship, Washington University School of Medicine
  • 1999
    Howard Hughes Medical Institute Summer Radiation Oncology Fellowship, Mallinckrodt Institute
  • 2005
    Member-in-Training Award for Outstanding RSNA Presentation in Radiation Oncology, American Association for Women Radiologists
  • 2006
    Member-in-Training Award for Outstanding ASTRO Presentation in Radiation Oncology, American Association for Women Radiologists
  • 2007
    Resident Research and Education Foundation Award, RSNA
  • 2007
    ASTRO plenary session presentation

Selected Publications

  1. Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. PLoS One. 2021; 16(6):e0252574.  View on PubMed
  2. Susko MS, Lazar AA, Wang CJ, Van Loon K, Feng M, Hope TA, Behr S, Anwar M. Use of advanced PET-volume metrics predicts risk of local recurrence and overall survival in anal cancer. PLoS One. 2021; 16(2):e0246535.  View on PubMed
  3. Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M. Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients. Oncologist. 2020 09; 25(9):772-779.  View on PubMed
  4. Wilkie JR, Mierzwa ML, Yao J, Eisbruch A, Feng M, Weyburne G, Chen X, Holevinski L, Mayo CS. Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy. Radiother Oncol. 2019 08; 137:167-174.  View on PubMed
  5. Xu MJ, Feng M. Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines? Semin Liver Dis. 2019 Feb; 39(1):43-52.  View on PubMed
  6. Yu Y, Feng M. Radiotherapy for Hepatocellular Carcinoma. Semin Radiat Oncol. 2018 10; 28(4):277-287.  View on PubMed
  7. Matuszak MM, Fuller CD, Yock TI, Hess CB, McNutt T, Jolly S, Gabriel P, Mayo CS, Thor M, Caissie A, Rao A, Owen D, Smith W, Palta J, Kapoor R, Hayman J, Waddle M, Rosenstein B, Miller R, Choi S, Moreno A, Herman J, Feng M. Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology. Med Phys. 2018 Oct; 45(10):e811-e819.  View on PubMed
  8. Pollom EL, Feng M, Chang DT. Comparing Modalities Using the National Cancer Database: Concerns With Rajyaguru et al. J Clin Oncol. 2018 08 20; 36(24):2557.  View on PubMed
  9. Parikh ND, Marshall VD, Green M, Lawrence TS, Razumilava N, Owen D, Singal AG, Feng M. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare. J Med Imaging Radiat Oncol. 2018 Oct; 62(5):673-681.  View on PubMed
  10. Maimela E, Alberts M, Bastiaens H, Fraeyman J, Meulemans H, Wens J, Van Geertruyden JP. Interventions for improving management of chronic non-communicable diseases in Dikgale, a rural area in Limpopo Province, South Africa. BMC Health Serv Res. 2018 05 04; 18(1):331.  View on PubMed
  11. Simeth J, Johansson A, Owen D, Cuneo K, Mierzwa M, Feng M, Lawrence TS, Cao Y. Quantification of liver function by linearization of a two-compartment model of gadoxetic acid uptake using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 2018 06; 31(6):e3913.  View on PubMed
  12. Feng M, Valdes G, Dixit N, Solberg TD. Machine Learning in Radiation Oncology: Opportunities, Requirements, and Needs. Front Oncol. 2018; 8:110.  View on PubMed
  13. Shilkrut M, Sapir E, Hanasoge S, Schipper MJ, Normolle DP, Ben-Josef E, Ensminger W, Lawrence TS, Feng M. Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. Am J Clin Oncol. 2018 04; 41(4):326-331.  View on PubMed
  14. Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, Parikh ND, Welling TH, Normolle D, Ten Haken RK, Lawrence TS. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Jan 01; 4(1):40-47.  View on PubMed
  15. Mayo CS, Moran JM, Bosch W, Xiao Y, McNutt T, Popple R, Michalski J, Feng M, Marks LB, Fuller CD, Yorke E, Palta J, Gabriel PE, Molineu A, Matuszak MM, Covington E, Masi K, Richardson SL, Ritter T, Morgas T, Flampouri S, Santanam L, Moore JA, Purdie TG, Miller RC, Hurkmans C, Adams J, Jackie Wu QR, Fox CJ, Siochi RA, Brown NL, Verbakel W, Archambault Y, Chmura SJ, Dekker AL, Eagle DG, Fitzgerald TJ, Hong T, Kapoor R, Lansing B, Jolly S, Napolitano ME, Percy J, Rose MS, Siddiqui S, Schadt C, Simon WE, Straube WL, St James ST, Ulin K, Yom SS, Yock TI. American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2018 03 15; 100(4):1057-1066.  View on PubMed
  16. Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper MJ, Feng M, Cuneo KC, Lawrence TS, Owen D. Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. Int J Radiat Oncol Biol Phys. 2018 03 15; 100(4):950-958.  View on PubMed
  17. Zhou J, Fang CX, Shen J, Schipper MJ, Zalupski MM, Minter RM, Simeone DM, Hart D, Eagle T, Kimmel GW, Vainshtein J, Lawrence TS, Feng M. Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy. Am J Clin Oncol. 2017 Oct; 40(5):517-522.  View on PubMed
  18. Suresh K, Owen D, Bazzi L, Jackson W, Ten Haken RK, Cuneo K, Feng M, Lawrence TS, Schipper MJ. Using Indocyanine Green Extraction to Predict Liver Function After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):131-137.  View on PubMed
  19. Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND, Feng M. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):122-130.  View on PubMed
  20. Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):40-47.  View on PubMed

Go to UCSF Profiles, powered by CTSI